These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 32292501)

  • 21. The changing landscape of gene editing in hematopoietic stem cells: a step towards Cas9 clinical translation.
    Dever DP; Porteus MH
    Curr Opin Hematol; 2017 Nov; 24(6):481-488. PubMed ID: 28806273
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR-Cas9 gene editing: Delivery aspects and therapeutic potential.
    Oude Blenke E; Evers MJ; Mastrobattista E; van der Oost J
    J Control Release; 2016 Dec; 244(Pt B):139-148. PubMed ID: 27498021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mutation-Independent Allele-Specific Editing by CRISPR-Cas9, a Novel Approach to Treat Autosomal Dominant Disease.
    Christie KA; Robertson LJ; Conway C; Blighe K; DeDionisio LA; Chao-Shern C; Kowalczyk AM; Marshall J; Turnbull D; Nesbit MA; Moore CBT
    Mol Ther; 2020 Aug; 28(8):1846-1857. PubMed ID: 32416058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
    Salsman J; Masson JY; Orthwein A; Dellaire G
    Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool.
    Sahel DK; Mittal A; Chitkara D
    J Pharmacol Exp Ther; 2019 Sep; 370(3):725-735. PubMed ID: 31122933
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the potential of genome editing CRISPR-Cas9 technology.
    Singh V; Braddick D; Dhar PK
    Gene; 2017 Jan; 599():1-18. PubMed ID: 27836667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Point: Treating Human Genetic Disease One Base Pair at a Time: The Benefits of Gene Editing.
    Katsanis N
    Clin Chem; 2018 Mar; 64(3):486-488. PubMed ID: 29490998
    [No Abstract]   [Full Text] [Related]  

  • 29. CRISPR/Cas9: targeted genome editing for the treatment of hereditary hearing loss.
    Farooq R; Hussain K; Tariq M; Farooq A; Mustafa M
    J Appl Genet; 2020 Feb; 61(1):51-65. PubMed ID: 31912450
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harnessing CRISPR/Cas systems for programmable transcriptional and post-transcriptional regulation.
    Mahas A; Neal Stewart C; Mahfouz MM
    Biotechnol Adv; 2018; 36(1):295-310. PubMed ID: 29197619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Recent developments in enhancing the efficiency of CRISPR/Cas9- mediated knock-in in animals].
    Li GL; Yang SX; Wu ZF; Zhang XW
    Yi Chuan; 2020 Jul; 42(7):641-656. PubMed ID: 32694104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome Engineering for Stem Cell Transplantation.
    Argani H
    Exp Clin Transplant; 2019 Jan; 17(Suppl 1):31-37. PubMed ID: 30777520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas Applications in Myotonic Dystrophy: Expanding Opportunities.
    Raaijmakers RHL; Ripken L; Ausems CRM; Wansink DG
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31357652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond Native Cas9: Manipulating Genomic Information and Function.
    Mitsunobu H; Teramoto J; Nishida K; Kondo A
    Trends Biotechnol; 2017 Oct; 35(10):983-996. PubMed ID: 28739220
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene Editing for Treatment and Prevention of Human Diseases: A Global Survey of Gene Editing-Related Researchers.
    Rocha LFM; Braga LAM; Mota FB
    Hum Gene Ther; 2020 Aug; 31(15-16):852-862. PubMed ID: 32718240
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An overview of currently available molecular Cas-tools for precise genome modification.
    Kondrateva E; Demchenko A; Lavrov A; Smirnikhina S
    Gene; 2021 Feb; 769():145225. PubMed ID: 33059029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and therapy with CRISPR advanced CRISPR based tools for point of care diagnostics and early therapies.
    Uppada V; Gokara M; Rasineni GK
    Gene; 2018 May; 656():22-29. PubMed ID: 29496558
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The delivery challenge: fulfilling the promise of therapeutic genome editing.
    van Haasteren J; Li J; Scheideler OJ; Murthy N; Schaffer DV
    Nat Biotechnol; 2020 Jul; 38(7):845-855. PubMed ID: 32601435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-Strand Annealing Plays a Major Role in Double-Strand DNA Break Repair following CRISPR-Cas9 Cleavage in
    Zhang WW; Matlashewski G
    mSphere; 2019 Aug; 4(4):. PubMed ID: 31434745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development and application of CRISPR/Cas9 technologies in genomic editing.
    Zhang C; Quan R; Wang J
    Hum Mol Genet; 2018 Aug; 27(R2):R79-R88. PubMed ID: 29659822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.